{"id":"NCT02638207","sponsor":"Octapharma","briefTitle":"Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy","officialTitle":"Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-27","primaryCompletion":"2019-09-05","completion":"2019-09-05","firstPosted":"2015-12-23","resultsPosted":"2021-02-16","lastUpdate":"2021-02-16"},"enrollment":142,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy"],"interventions":[{"type":"DRUG","name":"NewGam","otherNames":["Panzyga"]}],"arms":[{"label":"0.5 g/kg NewGam","type":"EXPERIMENTAL"},{"label":"1.0 g/kg NewGam","type":"EXPERIMENTAL"},{"label":"2.0 g/kg NewGam","type":"EXPERIMENTAL"}],"summary":"Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy","primaryOutcome":{"measure":"Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score","timeFrame":"at Week 24","effectByArm":[{"arm":"1.0 g/kg NewGam","deltaMin":0.7971,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["Bulgaria","Canada","Czechia","Germany","Hungary","Poland","Romania","Russia","Ukraine"]},"refs":{"pmids":["38353301","37378806","35038723"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":35},"commonTop":["Headache","Dermatitis allergic","Pyrexia","Blood pressure increased","Body temperature increased"]}}